Senti Biosciences officer has 1,384 shares withheld for tax

Senti Biosciences officer reports tax share withholding from RSU settlement.

Rhea-AI Filing Summary

Senti Biosciences officer reports tax share withholding from RSU settlement. On 02/02/2026, Pres. & Chief Med. & Dev. Officer Kanya Rajangam had 1,384 shares of Senti Biosciences common stock withheld at a price of $0 per share to cover income tax obligations on vested restricted stock units.

These shares were withheld by the company and the transaction did not involve an open market sale. Following this tax-related withholding, Rajangam directly beneficially owns 85,600 shares of Senti Biosciences common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 1,384 shares

Exercise Price or Tax Liability 1 txn

Insider Rajangam Kanya

Role Pres. & Chief Med. & Dev. Off.

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,384	$0.00	$0.00

Holdings After Transaction: Common Stock — 85,600 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Senti Biosciences (SNTI) report for Kanya Rajangam?

Senti Biosciences reported that officer Kanya Rajangam had 1,384 shares of common stock withheld on February 2, 2026 to cover income tax obligations from vested restricted stock units, rather than selling shares in the open market.

Was the Senti Biosciences (SNTI) insider transaction an open market sale?

No, the transaction was not an open market sale. The 1,384 shares of common stock were withheld by Senti Biosciences to satisfy income tax withholding and remittance obligations related to the net settlement of time-based restricted stock unit awards.

How many Senti Biosciences (SNTI) shares does Kanya Rajangam own after the transaction?

After the tax withholding transaction, Kanya Rajangam directly beneficially owns 85,600 shares of Senti Biosciences common stock. This figure reflects holdings following the withholding of 1,384 shares used to satisfy income tax obligations on vested RSUs.

What does transaction code F mean in the Senti Biosciences (SNTI) insider report?

Transaction code F indicates shares were withheld to pay taxes upon the vesting or settlement of equity awards. In this case, 1,384 shares of Senti Biosciences common stock were withheld in connection with the net settlement of time-based RSU awards.

What role does Kanya Rajangam hold at Senti Biosciences (SNTI)?

Kanya Rajangam serves as President & Chief Medical & Development Officer of Senti Biosciences. The reported insider transaction reflects tax-related share withholding connected to equity compensation rather than discretionary buying or selling in the market.

Does the Senti Biosciences (SNTI) insider transaction affect ownership form?

The filing shows that 85,600 shares of Senti Biosciences common stock are held with direct ownership by Kanya Rajangam after the transaction. The 1,384 withheld shares were retained by the company for tax obligations on RSU settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:17 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rajangam Kanya

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. & Chief Med. & Dev. Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		F		1,384(1)	D	$0	85,600	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of certain time-based restricted stock unit awards and does not represent an open market sale.

Remarks:

	/s/ Robert Cutler, attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.